TY - JOUR
T1 - GLP-1 based therapies
T2 - clinical implications for gastroenterologists
AU - Smits, Mark M
AU - van Raalte, Daniel H
AU - Tonneijck, Lennart
AU - Muskiet, Marcel H A
AU - Kramer, Mark H H
AU - Cahen, Djuna L
PY - 2016/4
Y1 - 2016/4
N2 - The gut-derived incretin hormone, glucagon-like peptide 1 (GLP-1) lowers postprandial blood glucose levels by stimulating insulin and inhibiting glucagon secretion. Two novel antihyperglycaemic drug classes augment these effects; GLP-1 receptor agonists and inhibitors of the GLP-1 degrading enzyme dipeptidyl peptidase 4. These so called GLP-1 based or incretin based drugs are increasingly used to treat type 2 diabetes, because of a low risk of hypoglycaemia and favourable effect on body weight, blood pressure and lipid profiles. Besides glucose control, GLP-1 functions as an enterogastrone, causing a wide range of GI responses. Studies have shown that endogenous GLP-1 and its derived therapies slow down digestion by affecting the stomach, intestines, exocrine pancreas, gallbladder and liver. Understanding the GI actions of GLP-1 based therapies is clinically relevant; because GI side effects are common and need to be recognised, and because these drugs may be used to treat GI disease.
AB - The gut-derived incretin hormone, glucagon-like peptide 1 (GLP-1) lowers postprandial blood glucose levels by stimulating insulin and inhibiting glucagon secretion. Two novel antihyperglycaemic drug classes augment these effects; GLP-1 receptor agonists and inhibitors of the GLP-1 degrading enzyme dipeptidyl peptidase 4. These so called GLP-1 based or incretin based drugs are increasingly used to treat type 2 diabetes, because of a low risk of hypoglycaemia and favourable effect on body weight, blood pressure and lipid profiles. Besides glucose control, GLP-1 functions as an enterogastrone, causing a wide range of GI responses. Studies have shown that endogenous GLP-1 and its derived therapies slow down digestion by affecting the stomach, intestines, exocrine pancreas, gallbladder and liver. Understanding the GI actions of GLP-1 based therapies is clinically relevant; because GI side effects are common and need to be recognised, and because these drugs may be used to treat GI disease.
KW - Gastrointestinal Diseases
KW - Glucagon-Like Peptide 1
KW - Humans
KW - Journal Article
KW - Research Support, Non-U.S. Gov't
KW - Review
U2 - https://doi.org/10.1136/gutjnl-2015-310572
DO - https://doi.org/10.1136/gutjnl-2015-310572
M3 - Article
C2 - 26786687
SN - 0017-5749
VL - 65
SP - 702
EP - 711
JO - Gut
JF - Gut
IS - 4
ER -